Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Tiagabine clinical data reported at congress this week

Sep. 6, 1996

Fosphenytoin launch imminent

Sep. 6, 1996

Mechanism-based enzyme inhibitor may serve as a lead for new anticonvulsants

Sep. 6, 1996

NS-2389: a potential new antidepressant

Sep. 6, 1996

Reversible MAO inhibitors from Hoechst Marion Roussel

Sep. 6, 1996

Lilly's olanzapine deemed approvable

Sep. 6, 1996

Antipsychotic dopaminergic compounds from E. Merck

Sep. 6, 1996

Lilly discloses new serotonergic agents

Sep. 6, 1996

NS-2710 in development for anxiety

Sep. 6, 1996

Melatonergic agents from ADIR

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...